Skip to main content
. 2023 Feb 15;62(19):2783–2793. doi: 10.2169/internalmedicine.0900-22

Figure 4.

Figure 4.

Kaplan-Meier curves of the high m-GPS and low m-GPS groups in the PS-matched cohort. (A) The PFS from the time of first-line nab-PTX+GEM initiation. The median PFS was 124 and 284 days in the high m-GPS and low m-GPS groups, respectively. The PFS was significantly shorter in the high m-GPS group than in the low m-GPS group (p<0.001, HR 2.598). (B) The OS from the time of first-line nab-PTX+GEM initiation. The median OS was 196 and 510 days in the high m-GPS and low m-GPS groups, respectively. The OS was significantly shorter in the high m-GPS group than in the low m-GPS group (p<0.001, HR 2.743). m-GPS: modified Glasgow prognostic score, PS: propensity score, PFS: progression-free survival, OS: overall survival, GEM: gemcitabine, PTX: paclitaxel, HR: hazard ratio